Abstract:
The use of antibody in targeted therapy has become the credible option
in the treatment of cancers due to its specificity and the fact that it is
associated with relatively lower toxicity compared to the other
treatment options like chemotherapy and radiotherapy. However,
Pharmaceutical
5N, 32N, 71N and 91N targeting vascular endothelial growth factor
receptor 2 (VEGFR2) were generated from camel. The nanobodies
University, Nanjingwere then screened by ELISA, immunoblotting and surface plasmon
210009, PR China.resonance (SPR) to select the nanobodies with high binding affinities.
The nanobodies 5N and 32N demonstrated the highest binding
affinities and therefore were selected for further studies. This was further confirmed by
flow cytometry assay. Additionally, the selected nanobodies 5N and 32N demonstrated
significant anti-angiogenic and anti-neoplastic abilities by restraining the proliferation of
VEGFR2 expressing human umbilical vein endothelial cells (HUVECs) in a dose-dependent
manner. These nanobodies are therefore potential anti-angiogenic agents which could
possibly be used in cancer therapy.
